NCT04827589View on ClinicalTrials.gov

Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

September 30, 2022

Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG

Tirabrutinib

Tablets administered orally

DRUG

Placebo

Tablets administered orally

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY